These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 5640168)

  • 1. Chronic toxicity of carboethoxyphthalazinohydrazine and its influence on the excretion of 5-hydroxyindoleacetic acid and the activity of 5-htp-decarboxylase in white rats.
    Chruściel M
    Br J Pharmacol Chemother; 1968 Jan; 32(1):104-12. PubMed ID: 5640168
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes resembling lupus erythematosus after prolonged treatment with Ro-4-4602, a potent inhibitor of 5-HTP-carboxyliase, in white rats.
    Chruściel M
    Eur J Pharmacol; 1969 Nov; 8(2):192-9. PubMed ID: 4188997
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatic amino acid decarboxylase: pH-dependence of substrates and inhibitors [proceedings].
    Bender DA; Coulson WF
    Biochem Soc Trans; 1977; 5(5):1353-6. PubMed ID: 21822
    [No Abstract]   [Full Text] [Related]  

  • 5. The interaction of 2,3,4-trihydroxybenzylhydrazine with DOPA decarboxylase from pig kidney.
    Borri Voltattorni C; Minelli A; Borri P
    Life Sci; 1981 Jan; 28(1):103-8. PubMed ID: 7225209
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of pyridoxal phosphate and L-dopapyridoxal phosphate on DOPA decarboxylase activity.
    Tran N
    Experientia; 1972 Sep; 28(9):1021-2. PubMed ID: 4665286
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic and renal drug-metabolizing enzyme expression.
    Runge-Morris M; Feng Y; Zangar RC; Novak RF
    Drug Metab Dispos; 1996 Jul; 24(7):734-7. PubMed ID: 8818569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Action of some DOPA decarboxylase inhibitors with reference to different types of convulsions].
    HEROLD M; CAHN J; HELBECQUE C; KABACOFF O
    C R Seances Soc Biol Fil; 1962; 156():1273-6. PubMed ID: 13954030
    [No Abstract]   [Full Text] [Related]  

  • 9. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine).
    Christenson JG; Dairman W; Udenfriend S
    Proc Natl Acad Sci U S A; 1972 Feb; 69(2):343-7. PubMed ID: 4536745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pathway for metabolism of dopa.
    O'Leary MH; Baughn RL
    Nature; 1975 Jan; 253(5486):52-3. PubMed ID: 1167399
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effects of vitamin B6 on L-aromatic amino acid decarboxylase in the organs of spontaneously hypertensive rats].
    Yoshimine T; Kuzuya F
    Nihon Ronen Igakkai Zasshi; 1975 Sep; 12(5):311-4. PubMed ID: 1237689
    [No Abstract]   [Full Text] [Related]  

  • 12. Fluctuations in DOPA decarboxylase activity with age.
    Awapara J; Saine S
    J Neurochem; 1975 Apr; 24(4):817-8. PubMed ID: 1123640
    [No Abstract]   [Full Text] [Related]  

  • 13. [Serotonin metabolism in acute renal ischemia].
    Ermolaev MV; Khovanskaia TP
    Patol Fiziol Eksp Ter; 1975; (5):82-4. PubMed ID: 1208141
    [No Abstract]   [Full Text] [Related]  

  • 14. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of human red blood cell 1-3,4-dihydroxyphenylalanine decarboxylating activity.
    Dairman W; Christenson JG
    Eur J Pharmacol; 1973 May; 22(2):135-40. PubMed ID: 4736669
    [No Abstract]   [Full Text] [Related]  

  • 16. Substrate specificity of aromatic-L-amino adid decarboxylase.
    Bosin TR; Buckpitt AR; Maickel RP
    Life Sci; 1974 Mar; 14(5):899-908. PubMed ID: 4828405
    [No Abstract]   [Full Text] [Related]  

  • 17. Endogenous inhibitors of DOPA decarboxylase in rat submandibular gland.
    Hashimoto S; Ikeno T; Hasegawa J; Nagatsu T; Kuzuya H
    Arch Oral Biol; 1980; 25(3):195-9. PubMed ID: 6930957
    [No Abstract]   [Full Text] [Related]  

  • 18. [ACTION OF CERTAIN L-DOPA/5-HTP DECARBOXYLASE INHIBITORS ON HYPOTHALAMO-HYPOPHYIAL NEUROSECRETION IN THE RAT].
    SOULAIRAC A; SOULAIRAC ML
    C R Seances Soc Biol Fil; 1964; 158():1445-7. PubMed ID: 14250544
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacology of several aromatic amino acid decarboxylase inhibitors].
    Uspenskiĭ AE; Dabagov NS; Skoldinov AP
    Biull Eksp Biol Med; 1978 Oct; 86(10):444-7. PubMed ID: 309344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of L-alpha-methyl-alpha-hydrazino-3,4 dihydroxyphenylpropionic acid with dopa-decarboxylase from pig kidney.
    Borri-Voltattorni C; Minelli A; Borri P
    FEBS Lett; 1977 Mar; 75(1):277-80. PubMed ID: 852589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.